Westover Capital Advisors LLC Has $628,000 Stake in Catalyst Pharmaceuticals, Inc. $CPRX

Westover Capital Advisors LLC lifted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 135.7% during the 2nd quarter, Holdings Channel reports. The fund owned 28,957 shares of the biopharmaceutical company’s stock after acquiring an additional 16,674 shares during the quarter. Westover Capital Advisors LLC’s holdings in Catalyst Pharmaceuticals were worth $628,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Catalyst Pharmaceuticals by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 8,495,580 shares of the biopharmaceutical company’s stock valued at $206,018,000 after purchasing an additional 64,486 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Catalyst Pharmaceuticals by 11.9% in the first quarter. Goldman Sachs Group Inc. now owns 3,135,473 shares of the biopharmaceutical company’s stock worth $76,035,000 after purchasing an additional 333,100 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Catalyst Pharmaceuticals by 3.7% during the second quarter. Geode Capital Management LLC now owns 2,866,683 shares of the biopharmaceutical company’s stock worth $62,214,000 after purchasing an additional 101,127 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Catalyst Pharmaceuticals by 6.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,326,771 shares of the biopharmaceutical company’s stock worth $32,174,000 after purchasing an additional 79,846 shares during the last quarter. Finally, Boston Partners increased its stake in shares of Catalyst Pharmaceuticals by 0.6% in the second quarter. Boston Partners now owns 1,282,722 shares of the biopharmaceutical company’s stock valued at $27,928,000 after buying an additional 7,397 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Wall Street Zen upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Sunday. Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Citigroup upped their target price on shares of Catalyst Pharmaceuticals from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Catalyst Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Oppenheimer reissued an “outperform” rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Buy” and an average target price of $32.67.

Catalyst Pharmaceuticals Stock Down 2.7%

Shares of CPRX stock opened at $22.56 on Tuesday. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of 13.67, a PEG ratio of 0.84 and a beta of 0.79. Catalyst Pharmaceuticals, Inc. has a 12 month low of $19.05 and a 12 month high of $26.58. The stock has a 50-day moving average price of $20.80 and a 200 day moving average price of $21.73.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Monday, September 25th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter. Catalyst Pharmaceuticals had a net margin of 37.36% and a return on equity of 40.78%. The company had revenue of $53.11 million for the quarter. Sell-side analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.9 earnings per share for the current fiscal year.

Catalyst Pharmaceuticals announced that its board has approved a share repurchase plan on Wednesday, October 1st that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the biopharmaceutical company to buy up to 8.3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its stock is undervalued.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, CEO Richard J. Daly sold 22,970 shares of the company’s stock in a transaction on Tuesday, August 26th. The shares were sold at an average price of $20.62, for a total transaction of $473,641.40. Following the completion of the sale, the chief executive officer owned 226,794 shares in the company, valued at approximately $4,676,492.28. The trade was a 9.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David S. Tierney sold 26,000 shares of the stock in a transaction on Wednesday, August 27th. The shares were sold at an average price of $20.20, for a total value of $525,200.00. Following the completion of the transaction, the director directly owned 379,620 shares in the company, valued at approximately $7,668,324. This trade represents a 6.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 243,970 shares of company stock valued at $4,927,241. 10.40% of the stock is currently owned by corporate insiders.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.